首页> 美国卫生研究院文献>BMJ Open >Protocol: 10-Valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trial

【2h】

Protocol: 10-Valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trial

机译：方案：10价肺炎球菌不可分型流感嗜血杆菌D结合疫苗（PHiD-CV10）与13价肺炎球菌结合疫苗（PCV13）作为加强剂量以扩大和加强澳大利亚土著儿童的中耳炎保护（PREVIX_BOOST）：一项随机对照试验的研究方案

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

and non-typeable (NTHi) are major otitis media pathogens that densely co-colonise the nasopharynx and infect the middle ear of Australian Aboriginal infants from very early in life. Our co-primary hypotheses are that at 18 months of age infants receiving 10-valent pneumococcal protein D conjugate vaccine (PHiD-CV10) compared with those receiving 13-valent pneumococcal conjugate vaccine (PCV13) as a booster at 12 months of age will have higher antibody levels to protein D and that infants receiving PCV13 will have higher antibody levels to PCV13-only serotypes 3, 6A and 19A.

机译：非典型性和非典型性（NTHi）是中耳炎的主要病原体，它们从幼年开始就将鼻咽密集地定殖并感染澳大利亚原住民婴儿的中耳。我们的共同主要假设是，在18个月大时接受12价肺炎球菌D结合疫苗（PHiD-CV10）的婴儿与在12个月大时接受13价肺炎球菌结合蛋白疫苗（PCV13）的婴儿相比较高的抗蛋白质D抗体水平，并且接受PCV13的婴儿对纯PCV13血清型3、6A和19A的抗体水平较高。

著录项

期刊名称 BMJ Open
作者
Victor M Oguoma; Nicole Wilson; Kim Mulholland; Mathuram Santosham; Paul Torzillo; Peter McIntyre; Heidi Smith-Vaughan; Anne Balloch; Mark Chatfield; Deborah Lehmann; Michael J Binks; Anne Chang; Jonathan Carapetis; Vicki Krause; Ross Andrews; Tom Snelling; Paul Licciardi; Peter Morris; Amanda Jane Leach;
展开▼
作者单位

展开▼
年(卷),期 2020(10),5
年度 2020
页码 -1
总页数 11
原文格式 PDF
正文语种
中图分类
关键词
otitis media; nasopharyngeal carriage; PHiD-CV10; PCV13;

机译：中耳炎;鼻咽运输;PHiD-CV10;PCV13;

相似文献

外文文献
中文文献
专利

1. Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6?months: PREVIX_COMBO, a 3-arm randomised controlled trial [J] . Amanda Jane Leach, Edward Kim Mulholland, Mathuram Santosham, BMC Pediatrics . 2021,第1期

机译：中耳炎媒体结果组合的10价肺炎球菌嗜血杆菌甲型蛋白D缀合物疫苗和13例肺炎球菌缀合物疫苗时间表在1-2-4-6〜2-6〜4-6〜6〜4-6个月：Previx_combo，3臂随机对照试验
2. A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand [J] . Lijoy Varghese, Louise Talbot, Andrea Govender, Applied health economics and health policy . 2018,第3期

机译：与新西兰通用大规模疫苗接种实施的13价肺炎球菌缀合物疫苗（PCV13）相比，10价肺炎球菌非典型血液植物甲型蛋白D缀合物（PHID-CV）的成本效益分析
3. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children - A randomized controlled trial [J] . Saez-Llorens Xavier, Rowley Stella, Wong Digna, Human vaccines & immunotherapeutics. . 2017,第6期

机译：10价肺炎球菌非典司嗜血杆菌流感蛋白D杂交疫苗对巴拉曼儿童急性中耳炎和鼻咽携带的疗效 - 一种随机对照试验
4. Microbiology of acute otitis media with perforation (AOMwiP) in Aboriginal children living in remote communities-monitoring the impact of 7-valent pneumococcal conjugate vaccine (7vPCV) [C] . Amanda Leach, Grant MacKenzie, Kim Hare, Lancefield International Symposium on Streptococci and Streptococcal Diseases . 2006

机译：具有穿孔（Aomwip）的急性中耳炎的微生物学，在偏远社区生活在偏远社区中的土着儿童 - 监测7价肺炎球菌缀合物疫苗的影响（7VPCV）
5. A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand [O] . Lijoy Varghese, Louise Talbot, Andrea Govender, -1

机译：在新西兰实施10价肺炎球菌不可分型流感嗜血杆菌D蛋白共轭疫苗（PHiD-CV）与13价肺炎球菌共轭疫苗（PCV13）的成本效益分析
6. Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial [O] . Amanda Jane Leach, Edward Kim Mulholland, Mathuram Santosham, 2021

机译：中耳炎10患者肺炎球菌血液嗜血糖尿病蛋白D缀合物疫苗和13价肺炎球菌缀合物疫苗时间表在1-2-4-6个月：Previx_Combo，3臂随机对照试验
7. Invasive Pneumococcal Disease and 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Coverage Among Children Aged Less Than or Equal to 59 Months, Selected U.S. Regions, 2010-2011 [R] . 2011

机译：侵入性肺炎球菌疾病和13价肺炎球菌结合疫苗（pCV13）覆盖率小于或等于59个月的儿童，2010 - 2011年选定的美国地区

摘要

著录项

相似文献

相关主题

期刊订阅